Combination treatment for newly diagnosed pediatric Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs—a PD-1 antibody and a JAK1 inhibitor—for children and teens with newly diagnosed Hodgkin lymphoma. The goal is to see if this combination can help treat the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 18 years old.
- You have been diagnosed with classic Hodgkin lymphoma and have not yet received treatment for it.
- You have at least one measurable tumor that can be seen on a scan.
- You are generally able to perform daily activities (ECOG 0-2).
- Your blood counts and organ function meet certain levels.
- You do not have other serious health conditions like active infections or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests a drug called tislelizumab (an immunotherapy that helps your immune system fight cancer) added to standard chemotherapy for older adults with newly diagnosed Hodgkin lymphoma. The goal is to see if adding this drug improves outcomes without too many side effects.
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.